CoreLink Announces FDA Clearance of Siber(R) Ti--3D Printed SI Joint Fusion System
ST. LOUIS, March 29, 2023 -- (Healthcare Sales & Marketing Network) -- CoreLink, LLC , a leading designer and manufacturer of innovative spinal implant systems announced today the 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its S... Devices, Orthopaedic, Neurosurgery, FDA CoreLink, Siber Ti, Sacroiliac Joint Fusion, spine surgery (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 29, 2023 Category: Pharmaceuticals Source Type: news
Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to Board
Spiral Therapeutics acquires assets from Otonomy, including data, patent rights, and inventory related to OTO-104, OTO-510, and OTO-413
Clinical data analysis suggests Spiral's lead candidate, SPT-2101, may offer improved treatment outcomes for Meniere'... Biopharmaceuticals, Acquisitions Spiral Therapeutics, Otonomy , Ménière's disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 29, 2023 Category: Pharmaceuticals Source Type: news
CereVasc Appoints Dr. Adel Malek Chief Medical Officer
BOSTON, March 28, 2023 -- (Healthcare Sales & Marketing Network) -- CereVasc, Inc., a privately held, clinical-stage, medical device company developing novel, minimally invasive treatments for neurological diseases, names Adel Malek, MD PhD as the company... Devices, Neurosurgery, Personnel CereVasc , eShunt System, hydrocephalus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 28, 2023 Category: Pharmaceuticals Source Type: news
DCISionRT(R) by PreludeDx(TM) Receives Advanced Diagnostic Laboratory Test (ADLT) Status Approval from the Centers for Medicare and Medicaid Services
LAGUNA HILLS, Calif., March 28, 2023 -- (Healthcare Sales & Marketing Network) -- Prelude Corporation (PreludeDx), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that the Centers for Medicare & Med... Diagnostics, Oncology PreludeDx, DCISionRT test, ductal carcinoma in situ (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 28, 2023 Category: Pharmaceuticals Source Type: news
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn(R) for the Treatment of ALS
Conference call and webcast at 8:00 a.m. ET
NEW YORK, March 27, 2023 -- (Healthcare Sales & Marketing Network) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, toda... Regenerative Medicine, Neurology, FDA BrainStorm Cell Therapeutics, NurOwn, amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 27, 2023 Category: Pharmaceuticals Source Type: news
New evidence demonstrates Smith and Nephew's COBLATION(TM) Technology can accelerate patient recovery with fewer complications compared with total tonsillectomy techniques
LONDON, March 23, 2023 -- (Healthcare Sales & Marketing Network) -- Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces results from new scientific research that shows its COBLATION Intracapsular Tonsillectomy (CIT) t... Devices, Surgery Smith & Nephew, COBLATION Intracapsular Tonsillectomy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 23, 2023 Category: Pharmaceuticals Source Type: news
Flare Therapeutics Announces Oversubscribed $123 Million Series B Financing
Financing round led by GordonMD® Global Investments LP and Pfizer Ventures, with participation from a world-class group of investors
Proceeds to support advancement of FX-909, a first-in-class PPARG inhibitor, into the clinic in 2023, along with con... Biopharmaceuticals, Oncology, Venture Capital Flare Therapeutics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2023 Category: Pharmaceuticals Source Type: news
U.S. FDA Grants GrayMatters Health 510(k) Clearance to Market Prism for PTSD
Non-Invasive, Self-Neuromodulation, Adjunct to Standard of Care Therapy Using Amygdala Derived EEG-fMRI Pattern Biomarkers to Help Patients with PTSD
HAIFA, Israel, March 21, 2023 -- (Healthcare Sales & Marketing Network) -- GrayMatters Health (GMH), d... Devices, Neurology, FDA GrayMatters Health, self-neuromodulation, PTSD (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 21, 2023 Category: Pharmaceuticals Source Type: news
NuVasive Specialized Orthopedics Expands Indications of Precice Limb Lengthening System to Treat Pediatric Patients
SAN DIEGO, March 20, 2023 -- (Healthcare Sales & Marketing Network) -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today anno... Devices, Orthopaedic, FDA NuVasive, limb lengthening, Precice (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 20, 2023 Category: Pharmaceuticals Source Type: news
Embolx Signs International Distribution Agreement
SUNNYVALE, Calif., March 16, 2023 -- (Healthcare Sales & Marketing Network) -- Embolx, Inc. - a medical device company developing microcatheters for arterial embolization procedures, today announced the signing of a distribution agreement with Cardiva Ita... Devices, Interventional, Distribution Embolx , Cardiva Italia, microcatheter, embolization (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 16, 2023 Category: Pharmaceuticals Source Type: news
Medtronic receives CE Mark approval for Affera(TM) Mapping and Ablation System to treat atrial arrhythmias
First of its kind, all-in-one Sphere-9 Catheter with pulsed field ablation, radiofrequency, and high density mapping integrated with intuitive mapping and navigation platform
DUBLIN, March 15, 2023 -- (Healthcare Sales & Marketing Network) -- Medtroni... Devices, Interventional, Cardiology, Regulatory Medtronic, Affera , Affera Prism-1, cardiac mapping, Sphere-9 (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 15, 2023 Category: Pharmaceuticals Source Type: news
Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies
Company is pioneering a novel approach by targeting fibrotic mediators that drive disease progression
Portfolio comprises three targets, each of which is measurable in plasma and correlates with disease severity
Proceeds will advance programs into cl... Biopharmaceuticals, Venture Capital Mediar Therapeutics (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 15, 2023 Category: Pharmaceuticals Source Type: news
Over 1,000 Patients Enrolled in Landmark SELUTION DeNovo Study
GENEVA, March 14, 2023 -- (Healthcare Sales & Marketing Network) -- MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo coronary randomized study. Recruitment is now a third of the way towards the target of 3... Devices, Interventional, Cardiology MedAlliance, Cordis , SELUTION SLR, drug eluting balloon (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 14, 2023 Category: Pharmaceuticals Source Type: news
NuVasive Celebrates 20-Year Milestone of the XLIF Procedure
NuVasive commemorates industry-defining innovation in the lateral procedural segment
SAN DIEGO, March 13, 2023 -- (Healthcare Sales & Marketing Network) -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transformin... Devices, Neurosurgery, Orthopaedic NuVasive, XLIF, interbody fusion, spine surgery (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 13, 2023 Category: Pharmaceuticals Source Type: news
QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
EQT Life Sciences, Droia Ventures, and Sanofi Ventures led the round
Financing supports clinical activities for Company's two lead programs in ALS and pipeline development
CAMBRIDGE, Mass., March 9, 2023 -- (Healthcare Sales & Marketing Network) -- ... Biopharmaceuticals, Neurology, Venture Capital QurAlis , amyotrophic lateral sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 9, 2023 Category: Pharmaceuticals Source Type: news
